泛亚洲适应临床实践指南:转移性非小细胞肺癌患者的管理——CSCO-ESMO倡议,获JSMO、KSMO、MOS、SSO和TOS认可
该指南基于ESMO 2016版转移性非小细胞肺癌指南,由CSCO与ESMO倡议,联合日本、韩国、马来西亚、新加坡和中国台湾的肿瘤学会专家,考虑亚洲人群的种族差异进行适应性调整,形成共识意见。投票基于科学证据,独立于六个亚洲国家的当前治疗实践、药物可及性和报销情况。审稿过程中发布的ESMO 2018更新版指南也在最终阶段被纳入考虑。
要点
- 指南由CSCO与ESMO倡议,六个亚洲地区肿瘤学会专家参与制定共识。
- 旨在将ESMO 2016指南适应亚洲患者转移性NSCLC治疗的种族差异。
- 投票基于科学证据,独立于各国治疗实践及药物可及性与报销情况。
核心结论
- 该泛亚洲适应指南代表了六个亚洲地区肿瘤学会专家对转移性NSCLC治疗的共识意见。
研究设计与样本
- 基于ESMO 2016版转移性NSCLC临床实践指南进行适应性调整的共识制定项目。
- 由CSCO与ESMO倡议,专家来自中国、日本、韩国、马来西亚、新加坡和中国台湾的肿瘤学会。
- 投票基于科学证据,独立于六个参与亚洲国家的当前治疗实践及药物可及性与报销情况。
- 审稿过程中发布的ESMO 2018更新版指南在最终制定阶段也被纳入考虑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.
引用
- Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019. PMID: 30596843. doi:10.1093/annonc/mdy554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。